I do, and I’m pretty militant about distracted driving. Long drives are captive time to think. Not rarely is there a “oh snap, that needs to get done on Tuesday not Friday” moment. Adjusting that hands free in natural language is useful.
I like this take. With its reduction to “survival of the fittest” slogan, it is easy to forget that Evolution can be “subjective”, imprecise in the problems it is solving.
Circling the wagons and tending our own garden is a nice ideal, but is no panacea just because we build some factories in Cleveland, celebrate the end of Globalism , claim ‘US energy independence’ (that’s gotten quiet lately.) reassessing our footprint? Yes great idea. Large poorly thought-through snap actions because headlines are needed? No thanks.
What you say is all true. Put down that book and take a trip to a Corpus Christi Texas city council meeting (eg), and help get all that silly confusion sorted out.
To add a somewhat cynical view, a significant part of the original motivation for the ranibizumab (Lucentis) development was due to pricing arbitrage across diseases. bevicizumab was priced based on uses in cancer indications with a “large” volume (many mls) used for systemic infusion. The same product injected into the eye, in say a 1:1000 volume, could be efficacious for AMD, but pricing per volume would be trivial amount at the bevi cost per volume. So they tweaked the active ingredient to a new product (exact same mechanism ) and raised the price per volume to a market standard cost per treatment. There may be some pk-type benefits to the derivative , but the pricing context is an industry case study.
I agree with you that AAV is clearly a useful tool but at times the low levels of self discipline and scientific rigor that the field has applied to dosing is disappointing at best and scary at times. This includes use of other vector types such as by bluebirdbio and even the Jesse Gelsinger tragedy. “If a little is good then more is better” is a crazy and lazy way to apply and optimize these technologies.
I suspect there is a deep sequencing service that is non CLIA and cheap. True. they may not be trustworthy with the data. That said, there are steps here where the data is put into Claude. Do we trust that ?
I think their point is not the ESG component, but firms with traditionally irrational valuations (à la GameStop) for which index inclusion exceptions have been made to facilitate short term liquidity for IPO participants. Seems as though one should be able to hold the broad market less that component.
This is interesting.
As a naive user I’ve gotten the gut feeling of commoditization among the models. I assumed the data center capacity push is intended to be the differentiator but that still seems utility-like over time. (and the data centers in space concept seems like good PR and IR, but to me, technically… ambitious)
(not intending ot be snarky, but this isn't my area of knowledge in the least.) Didn't the AI organizations 'get it both ways' when they trained on vast collection of works under copyright and then purely "own' the outcome?
Put this way, this seems reasonable. Beyond cell therapy, I don't thin the cost of drug is the motivation for not making it more freely available. 'Misuse' leading to potential liability or unjustified bad outcomes, along with some regulatory burden seems like the issue.
Knowing whether drugs work isn’t trivial. Patients are typically very heterogeneous in their responses to drugs. For example, pembrolizumab (the most successful cancer drug ever) typically only works in, say 30% of patients depending of the cancer type. Just throwing therapeutic ideas out there and letting physicians sort out how to use them and in which patients, isn’t a panacea. Looking at clinical data can be like star gazing even in planned studies. Structured, statistically powered studies, and costly rigorous assays on biomarkers and correlative studies are essential for understanding how and in what patients drugs are working. I’m all for expanding access to drugs, and there is abundant waste and greed in big Pharma and venture, but there are also people doing hard expensive science, medicine and manufacturing. Im not sure I have the answer. A “yelp for medicine” won’t improve immediate outcomes, nor longer term understanding and progress. A great and excruciating read about the tension there is a real-time blog (the story’s story) that was written by Jake Seliger unt he passed in 2023.